HomeCompareSYNH vs GBDC

SYNH vs GBDC: Dividend Comparison 2026

SYNH yields 4.65% · GBDC yields 11.86%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 GBDC wins by $20.82M in total portfolio value
10 years
SYNH
SYNH
● Live price
4.65%
Share price
$42.98
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$27.1K
Annual income
$626.90
Full SYNH calculator →
GBDC
GBDC
● Live price
11.86%
Share price
$12.65
Annual div
$1.50
5Y div CAGR
51.1%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.85M
Annual income
$16,450,733.83
Full GBDC calculator →

Portfolio growth — SYNH vs GBDC

📍 GBDC pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSYNHGBDC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SYNH + GBDC cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
SYNH pays
GBDC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SYNH
Annual income on $10K today (after 15% tax)
$395.53/yr
After 10yr DRIP, annual income (after tax)
$532.87/yr
GBDC
Annual income on $10K today (after 15% tax)
$1,007.91/yr
After 10yr DRIP, annual income (after tax)
$13,983,123.76/yr
At 15% tax rate, GBDC beats the other by $13,982,590.89/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SYNH + GBDC for your $10,000?

SYNH: 50%GBDC: 50%
100% GBDC50/50100% SYNH
Portfolio after 10yr
$10.44M
Annual income
$8,225,680.37/yr
Blended yield
78.80%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on SYNH right now

SYNH
Analyst Ratings
12
Buy
11
Hold
1
Sell
Consensus: Buy
Price Target
$72.00
+67.5% upside vs current
Range: $25.00 — $105.00
Altman Z
1.4
Piotroski
7/9
GBDC
Analyst Ratings
6
Buy
5
Hold
Consensus: Buy
Price Target
$14.00
+10.7% upside vs current
Range: $13.00 — $15.00
Altman Z
0.6
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SYNH buys
0
GBDC buys
0
No recent congressional trades found for SYNH or GBDC in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSYNHGBDC
Forward yield4.65%11.86%
Annual dividend / share$2.00$1.50
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%51.1%
Portfolio after 10y$27.1K$20.85M
Annual income after 10y$626.90$16,450,733.83
Total dividends collected$5.5K$20.43M
Payment frequencyquarterlyquarterly
SectorStockBDC
Analyst consensusBuyBuy
Analyst price target$72.00$14.00

Year-by-year: SYNH vs GBDC ($10,000, DRIP)

YearSYNH PortfolioSYNH Income/yrGBDC PortfolioGBDC Income/yrGap
1← crossover$11,165$465.33$12,492$1,791.70$1.3KGBDC
2$12,432$485.57$16,527$3,160.58$4.1KGBDC
3$13,808$505.31$23,588$5,904.90$9.8KGBDC
4$15,299$524.50$37,141$11,901.65$21.8KGBDC
5$16,913$543.12$66,205$26,463.38$49.3KGBDC
6$18,658$561.14$137,452$66,612.65$118.8KGBDC
7$20,543$578.54$342,372$195,298.53$321.8KGBDC
8$22,576$595.30$1,053,292$686,954.33$1.03MGBDC
9$24,768$611.43$4,111,439$2,984,416.95$4.09MGBDC
10$27,129$626.90$20,849,974$16,450,733.83$20.82MGBDC

SYNH vs GBDC: Complete Analysis 2026

SYNHStock

Syneos Health, Inc. provides biopharmaceutical outsourcing solutions company in North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. It operates through two segments, Clinical Solutions and Commercial Solutions. The Clinical Solutions segment offers services for the development of diagnostics, drugs, biologics, devices, and digital therapeutics in the Phase I to IV of clinical development. This segment also provides individual services, including product development and regulatory consulting, project management, protocol development, investigational site recruitment, clinical monitoring, technology-enabled patient recruitment and engagement, clinical home health, clinical trial diversity, biometric, and regulatory affair services. The Commercial Solutions segment provides commercialization services, including deployment solutions, communications solutions, such as public relations, advertising, and medical communication services; and consulting services to the pharmaceutical, biotechnology, and healthcare industries. The company was formerly known as INC Research Holdings, Inc. and changed its name to Syneos Health, Inc. in January 2018. Syneos Health, Inc. was incorporated in 2010 and is headquartered in Morrisville, North Carolina.

Full SYNH Calculator →

GBDCBDC

Golub Capital BDC, Inc. (GBDC) is a business development company and operates as an externally managed closed-end non-diversified management investment company. It invests in debt and minority equity investments in middle-market companies that are, in most cases, sponsored by private equity investors. It typically invests in diversified consumer services, automobiles, healthcare technology, insurance, health care equipment and supplies, hotels, restaurants and leisure, healthcare providers and services, IT services and specialty retails. It seeks to invest in the United States. It primarily invests in first lien traditional senior debt, first lien one stop, junior debt and equity, senior secured, one stop, unitranche, second lien, subordinated and mezzanine loans of middle-market companies, and warrants.

Full GBDC Calculator →
📬

Get this SYNH vs GBDC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SYNH vs SCHDSYNH vs JEPISYNH vs OSYNH vs KOSYNH vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.